[The responsibility of the ophthalmologist when using drugs which are uneconomic from the perspective of the pharmaceutical industry].
Menéndez de Lucas
J A
JA
Morcillo Laiz
R
R
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002444:Cefuroxime / Q000600:supply & distribution / Q000627:therapeutic use; D004339:Drug Compounding; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D007880:Legislation, Drug; D009885:Ophthalmology; D013030:Spain; D014221:Triamcinolone / Q000600:supply & distribution / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014221:Triamcinolone; D000068258:Bevacizumab; D002444:Cefuroxime